Article

Fibrin glue offers alternative to sutures

Author(s):

The use of fibrin glue during pterygium surgery has been gaining in popularity. Generally, investigators from different institutions have reported the glue to be a safe and effective alternative to sutures that can effectively reduce surgical time as well as postoperative pain and discomfort.

Some complications also have been associated with this technique, including graft displacement and dehiscence and a higher recurrence rate of the pterygia.

Three groups of investigators recently reported their findings on the use of fibrin glue in surgery.

Sathish Srinivasan, FRCSEd, FRCOphth, and Allan Slomovic, MD, from the Toronto Western Hospital, Toronto, conducted a single-center retrospective chart review. They applied fibrin glue to conjunctival autografts during primary pterygium surgery and wanted to evaluate the safety, efficacy, and complication rate following this procedure.

"Traditionally, the autografts have been sutured in place using either absorbable or nonabsorbable sutures. Fibrin glue has been receiving increasing attention recently for attaching the autografts," he added.

The fibrin glue (Tisseel, Baxter) is comprised of two components-a sealant protein made of human plasminogen, fibrinogen and fibrinonectin, and factor XIII reconstituted in a bovine aprotinin, and a sealing component made of thrombin reconstituted in calcium chloride. The components are combined and applied to the desired area, Dr. Srinivasan explained.

"An important step is to obtain an autograft that is about 1 mm more than the size of the conjunctival defect. This extra 1 mm of tissue is tucked under the cut edge of the conjunctiva to obtain good apposition," he said. "No sutures were used in the procedure. This tucking of tissue all along the cut margins of the conjunctiva improves the stability of the graft."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.